Γ
Skip to content

🔬 Advanced Recombinant Humanized Collagen Technology

🏆 AS SEEN IN ALLURE

✓ FDA REGISTERED FACILITY

  • To home
  • Personal Center
  • To home
ProtYouth® ProtYouth®
ProtYouth® ProtYouth®
  • Search

    Something went wrong. Please try again!

  • Log in
  • Cart
  • USD | $

    Change country

    Update your country and language to be accurate with the place you're browsing from.

Dull & Uneven Skin Tone

instant rescue & glow
ProtYouth Collagen All-In Instant Awakening Serum ProtYouth Collagen All-In Instant Awakening Serum

ProtYouth Collagen All-In Instant Awakening Serum

Regular price $89.00
Fine Lines & Wrinkles
ProtYouth T16 Recombinant Humanized Collagen Serum Travel Size ProtYouth T16 Recombinant Humanized Collagen Serum Travel Size

ProtYouth T16 Recombinant Humanized Collagen Serum Travel Size

Regular price $79.00
Fine Lines & Wrinkles
ProtYouth T16 Recombinant Humanized Collagen Serum ProtYouth T16 Recombinant Humanized Collagen Serum

ProtYouth T16 Recombinant Humanized Collagen Serum

Regular price $449.00

What Is the Connection Between Type III Collagen and Melasma? From Clinical Trials to Daily Skincare: A New Frontier in Recombinant Humanized Type III Collagen.

Melasma has long been one of the most complex challenges in dermatological care. Historically, discussions around melasma focused almost exclusively on melanin inhibition. As scientific research has deepened, photoaging, inflammation, dermal microenvironments, and structural skin degradation have gradually been integrated into the study of melasma. In 2026, a groundbreaking clinical trial evaluating recombinant humanized Type III collagen directly introduced this biomaterial into melasma treatment protocols.

This raises a compelling question: Why is Type III collagen being connected to melasma?


A Split-Face Randomized Trial Explores the Role of Type III Collagen in Melasma

In a 2026 study published in Dermatologic Therapy titled "Intradermal Recombinant Humanized Collagen Type III for Melasma: Split-Face Randomized Comparison With Tranexamic Acid," authors Wenjie Li, Juan Li, Huiyun Fan, and colleagues evaluated 20 female subjects with bilateral melasma (mean age 42.2 ± 5.15 years).

The study utilized a randomized split-face design. One side received intradermal injections of 4 mg/mL recombinant humanized Type III collagen (rhCol III), while the contralateral side was treated with 50 mg/mL tranexamic acid (TXA), administered monthly over 5 sessions.

Following treatment, both sides demonstrated statistically significant reductions in Hemi-mMASI scores from baseline ($$p < 0.00$$), with both treatment modalities achieving a 40% clinical response rate. Notably, moderate-to-severe injection pain was reported by 85% of subjects on the TXA side, compared to only 30% on the rhCol III side.

During a 4-month post-treatment follow-up period, no significant recurrences or severe adverse events were observed. The trial also noted an exploratory finding: periocular wrinkle parameters showed more pronounced improvement on the rhCol III treated side.

While the sample size was modest, this study delivers a clear signal: recombinant humanized Type III collagen is entering human clinical research for melasma management.

Why Is Melasma Research Focusing on Collagen?

Although melasma presents visually as hyperpigmentation, the underlying cutaneous pathophysiology is far more complex. Prolonged UV exposure disrupts pigment metabolism while simultaneously driving photoaging processes. Dermal extracellular matrix (ECM) degradation, persistent subclinical inflammation, and structural instability between skin layers all contribute to melasma pathology.

Type III collagen is an essential structural protein within the dermal extracellular matrix, intimately tied to tissue repair, architectural support, and dermal microenvironment stability.

Consequently, researchers are increasingly examining melasma through a "dermal microenvironment" framework: beyond suppressing melanogenesis, attention is shifting to how dermal architecture, inflammatory signaling, and collagen networks evolve. The clinical study highlighted potential mechanisms including extracellular matrix remodeling, anti-inflammation, and regulation of oxidative stress. While these pathways require further scientific validation, they significantly broaden the therapeutic scope of melasma research. Melasma management is expanding from merely assessing "pigment darkness" toward addressing comprehensive dermal health.

Bridging Injections and Topical Skincare: Expanding Scenarios for Recombinant Type III Collagen

While clinical trials explore intradermal rhCol III injections, ProtYouth formulates recombinant humanized Type III collagen into daily topical skincare solutions. For consumers, this signifies that the same foundational recombinant Type III collagen technology is bridging the gap between clinical dermatology research and daily home care.

Products like ProtYouth T8 and T16 are engineered around recombinant humanized Type III collagen, each targeting distinct skin concerns. T8 focuses primarily on hydration, transepidermal water loss (TEWL), and facial redness, whereas T16 delivers concentrated care for multi-zone wrinkles. Users can select formulas according to their specific skin needs.

A key distinction must be recognized: clinical studies evaluate intradermal rhCol III injections for melasma therapeutic performance, whereas topical skincare focuses on long-term improvements in skin barrier hydration, redness reduction, and textural smoothness. Aligning these two data streams provides a complete view of how recombinant humanized Type III collagen transitions from scientific discovery to daily application.

Managing Dryness and Redness: Stabilizing the Skin Barrier

For skin prone to dryness, transient redness, or environmental reactivity, hydration and barrier stability represent crucial daily metrics.The single-ingredient ProtYouth T8 Recombinant Humanized Collagen Serum features an 8-repeat tandem core functional domain of Recombinant Type III Collagen, delivering 2 mg of recombinant collagen per single-dose ampoule.In a 28-day human efficacy trial involving 30 women aged 20–45:

  • Stratum corneum hydration: Increased by 43.50%
  • Transepidermal water loss (TEWL): Decreased by 20.30%
  • Facial redness intensity: Decreased by 18.90%
  • Sebum secretion: Decreased by 18.07%

These parameters directly reflect noticeable daily skin benefits: improved moisture retention, enhanced comfort, and reduced visible redness. For individuals navigating hyperpigmentation, maintaining robust sun protection and skin barrier integrity forms a critical foundation of daily care.

Addressing Co-occurring Expression Lines: Targeted Care with T16

Melasma frequently affects mature demographics. As age advances, pigment concerns often coincide with emerging under-eye lines, crow's feet, and tear trough wrinkles.

ProtYouth T16 Recombinant Humanized Collagen is similarly built around recombinant humanized Type III collagen, utilizing a high-density 16-repeat tandem functional domain structure delivering 2 mg of active collagen per ampoule.In a 28-day clinical evaluation involving 31 women aged 39–55:

  • Under-eye wrinkle area: Reduced by 34.46%
  • Crow's feet area (lateral canthus): Reduced by 38.64%
  • Tear trough line area: Reduced by 31.40%
  • Inner eye corner wrinkle area: Reduced by 33.16%

For those managing both tone irregularities and structural lines, daily skincare can be approached systematically: maintaining daytime sun protection and barrier stability, followed by targeted collagen care tailored to primary structural concerns.

A New Research Pathway for Type III Collagen and Melasma

This 2026 clinical study establishes an exciting direction for recombinant humanized Type III collagen. From foundational studies in collagen architecture and tissue repair to clinical exploration in melasma and human data for topical skincare, the application scope of Type III collagen continues to expand.

For consumers, navigating this evolving science is straightforward. By identifying whether primary concerns center on pigment, dryness, redness, or wrinkles, individuals can align their choices with clinical and human efficacy data corresponding to specific collagen types.

ProtYouth’s targeted product architectures transform "collagen skincare" from a generic marketing buzzword into a precise, scientifically backed solution: adapting the same core collagen technology to distinct real-world skincare needs. As further clinical research and human efficacy data emerge, our understanding of the relationship between Type III collagen, melasma, photoaging, and mature skin health will become clearer than ever.

Reference

Li W, Li J, Fan H, Cui F, Rang Z. Intradermal Recombinant Humanized Collagen Type III for Melasma: Split-Face Randomized Comparison With Tranexamic Acid. Dermatologic Therapy, 2026. DOI: 10.1155/dth/2727867.

ProtYouth®

ProtYouth is more than a brand, it is a promise, a promise to show every consumer how technology can transform into beauty.

Explore

  • About Us
  • Technology
  • Rewards
  • FAQ's
  • Contact Us
  • Track your Order
Explore
  • About Us
  • Technology
  • Rewards
  • FAQ's
  • Contact Us
  • Track your Order

Policies

  • Privacy Policy
  • Refund Policy
  • Shipping Policy
  • Terms of Service
Policies
  • Privacy Policy
  • Refund Policy
  • Shipping Policy
  • Terms of Service

Newsletter

Copyright © 2026 ProtYouth. All rights reserved.

Payment methods
  • American Express
  • Diners Club
  • Discover
  • Mastercard
  • PayPal
  • Visa

Orders $500+ Include a Free Travel Size Serum

Secure Checkout with Trusted Payment Protection

Free Shipping on Qualified Orders & Easy Returns

Your cart

It’s a little
empty here

You cart is currently empty Start Shopping
Replicate successful
Choose options

Quick cart is currently empty

No product has been selected yet.

  • Choosing a selection results in a full page refresh.

WE USE COOKIES

Some of them are essential while others are used to serve you a customized shopping experience.